Skip Navigation

Vaccine Safety Bibliography - November 2012

1.   Evaluation of vaccination recall letter system for medicaid-enrolled children aged 19-23 months - montana,  2011. MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61:811-5.

2.   Influenza vaccine 2012-2013. Med Lett Drugs Ther. 2012 Oct 1; 54(1400):77-8.

3.   Male vaccination against human papillomavirus. Br Dent J. 2012 Oct 12;213(7):359.

4.   New malaria vaccine reduces malaria by half in African children. J Paediatr Child Health. 2012 Oct; 48(10):945.

5.   Progress towards eradicating poliomyelitis: Afghanistan and Pakistan, January  2011-August 2012. Wkly Epidemiol Rec. 2012 Oct 5; 87(40):381-8.

6.   Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine  for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61:816-9.

7.   Abedi GR, Mutuc JD, Lawler J, Leroy ZC, Hudson JM, Blog DS, Schulte CR, Rausch-Phung E, Ogbuanu IU, Gallagher K, Kutty PK. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. Vaccine. 2012 Oct 3. [Epub  ahead of print].

8.   Ahlers-Schmidt CR, Hart T, Chesser A, Williams KS, Yaghmai B, Shah-Haque S, Wittler RR. Using human factors techniques to design text message reminders for childhood immunization. Health Educ Behav. 2012 Oct; 39(5):538-43.

9.   Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis. 2012 Oct; 31(10):2549-57.

10.   Asay GR, Cho BH, Lorick SA, Tipton ML, Dube NL, Messonnier ML. Coordination Costs for School-Located Influenza Vaccination Clinics, Maine, 2009 H1N1 Pandemic. J Sch Nurs. 2012 Oct; 28(5):328-35.

11.   Aspa J. The Future Is Now in Community-Acquired Pneumonia: Cardiovascular Complications and Conjugate Vaccines. Arch Bronconeumol. 2012 Oct;48(10):347-348.

12.  Aydin S, Guven T, Sahin I, Aksoy A, Kendir Y, Ilhan MN, Citil C, Catak Z, Ustun C. The effects of fever on hormone ghrelins, immunoglobulins, and heat shock protein 70 expression after swine flu vaccinations. Endocrine. 2012 Oct; 42(2):352-8.

13.  Barbosa CM, Terreri MT, Rosário PO, de Moraes-Pinto MI, Silva CA, Hilário MO. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin Exp Rheumatol. 2012 Sep-Oct; 30(5):791-8.

14.  Baron-Epel O, Madjar B, Gerfat R, Rishpon S. Trust and the demand for autonomy may explain the low rates of immunizations among nurses. Hum Vaccin Immunother. 2012 Oct 29;9(1). [Epub ahead of print].

15.  Barr IG, Jelley LL. The Coming Era of Quadrivalent Human Influenza Vaccines:  Who will Benefit? Drugs. 2012 Oct 30. [Epub ahead of print].

16.  Bechini A, Levi M, Boccalini S, Tiscione E, Balocchini E, Canessa C, Azzari C, Bonanni P. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy. Vaccine. 2012 Oct 5;30(45):6396-401.

17.  Bednarczyk RA, Davis R, Ault K, Orenstein W, Omer SB. Sexual Activity-Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds. Pediatrics. 2012 Oct 15. [Epub ahead of print].

18.  Bellido-Blasco JB, Sabater-Vidal S, Salvador-Ribera MD, Arnedo-Pena A, Tirado-Balaguer MD, Meseguer-Ferrer N, Silvestre-Silvestre E, Romeu-García MA, Herrero-Carot C, Moreno-Muñoz MR. Rotavirus vaccination effectiveness: A case-case study in the EDICS project, Castellón (Spain). Vaccine. 2012 Oct 25. [Epub ahead of print].

19.  Ben Amor I, Louati N, Khemekhem H, Dhieb A, Rekik H, Mdhaffar M, Gargouri J.  [Red blood cell immunization in haemoglobinopathie: About 84 cases.]. Transfus Clin Biol. 2012 Oct 25. [Epub ahead of print].

20.  Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U, Dagan R; on behalf of the Israeli Bacteremia and Meningitis Active Surveillance Group. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 2012 Oct 12; 30(46):6600-6607.

21.  Benhafid M, Rguig A, Trivedi T, Elqazoui M, Teleb N, Mouane N, Maltouf AF, Parashar U, Patel M, Aouad RE. Monitoring of rotavirus vaccination in Morocco: Establishing the baseline burden of rotavirus disease. Vaccine. 2012 Oct 12; 30(46):6515-20.

22.  Benn CS, Aaby P. Diphtheria-tetanus-pertussis vaccination administered after  measles vaccine: increased female mortality? Pediatr Infect Dis J. 2012 Oct; 31(10):1095-7.

23.  Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules  and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines-prognosis and outcome after booster vaccination. Eur J Pediatr. 2012 Oct 11. [Epub ahead of print].

24.  Berry JG, Ryan P, Gold MS, Braunack-Mayer AJ, Duszynski KM; for the Vaccine Assessment Using Linked Data (VALiD) Working Group. A randomised controlled trial to compare opt-in and opt-out parental consent for childhood vaccine safety surveillance using data linkage. J Med Ethics. 2012 Oct; 38(10):619-625.

25.  Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E. Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59(R)-Adjuvanted,  A/H5N1, Pre-Pandemic Influenza Vaccine in Adult and Elderly Subjects. Clin Vaccine Immunol. 2012 Oct 17. [Epub ahead of print].

26.  Birlea M, Owens GP, Eshleman EM, Ritchie A, Traktinskiy I, Bos N, Seitz S, Yevgeniy A, Mahalingam R, Gilden D, Cohrs RJ. Human Anti-Varicella Zoster Virus (VZV) Recombinant Monoclonal Antibody Produced after Zostavax Immunization Recognizes gH/gL Complex and Neutralizes VZV Infection. J Virol. 2012 Oct 17. [Epub ahead of print].

27.  Björkman I, Sanner MA. The Swedish A(H1N1) vaccination campaign-Why did not all Swedes take the vaccination? Health Policy. 2012 Oct 5. [Epub ahead of print].

28.  Blank PR, Bonnelye G, Ducastel A, Szucs TD. Attitudes of the General Public and General Practitioners in Five Countries towards Pandemic and Seasonal Influenza Vaccines during Season 2009/2010. PLoS One. 2012; 7(10):e45450.

29.  Blasi F, Aliberti S, Mantero M, Centanni S. Compliance with anti-H1N1 vaccine among healthcare workers and general population. Clin Microbiol Infect. 2012 Oct;18 Suppl 5:37-41.

30.  Bonati M, Clavenna A. Seasonal influenza immunization in early infancy? BMC Public Health. 2012 Oct 15;12(1):873. [Epub ahead of print].

31.  Boom JA, Sahni LC, Payne DC, Gautam R, Lyde F, Mijatovic-Rustempasic S, Bowen MD, Tate JE, Rench MA, Gentsch JR, Parashar UD, Baker CJ. Symptomatic infection and detection of vaccine and vaccine-reassortant rotavirus strains in 5 children: a case series. J Infect Dis. 2012 Oct;206(8):1275-9.

32.  Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G 2nd, Ziegler JB, Stoney T, Heron L, Lambert S, Mesaros N, Peddiraju K, Miller JM. Three-Year Antibody Persistence and Safety following a Single Dose of Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Hib-Primed Toddlers. Pediatr Infect Dis J. 2012 Oct 17. [Epub ahead of print].

33.  Brien S, Kwong JC, Charland KM, Verma AD, Brownstein JS, Buckeridge DL. Neighborhood Determinants of 2009 Pandemic A/H1N1 Influenza Vaccination in Montreal, Quebec, Canada. Am J Epidemiol. 2012 Oct 16. [Epub ahead of print].

34.  Brookhart MA, Walker AM, Lu Y, Polakowski L, Li J, Paeglow C, Puenpatom T, Izurieta H, Daniel GW. Characterizing Vaccine-associated Risks Using Cubic Smoothing Splines. Am J Epidemiol. 2012 Oct 25. [Epub ahead of print].

35.  Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, Scott DA. Antibody Responses to Routine Pediatric Vaccines Administered with 13-valent Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J. 2012 Oct 25. [Epub ahead of print].

36.  Brydak LB, Wočniak Kosek A, Nitsch-Osuch A. Influenza vaccines and vaccinations in Poland - past, present and future. Med Sci Monit. 2012 Oct 31; 18(11):RA166-171.

37.  Burwen DR, Sandhu SK, Macurdy TE, Kelman JA, Gibbs JM, Garcia B, Markatou M,  Forshee RA, Izurieta HS, Ball R; the Safety Surveillance Working Group. Surveillance for Guillain-Barré Syndrome After Influenza Vaccination Among the Medicare Population, 2009-2010. Am J Public Health. 2012 Oct; 102(10):1921-1927.

38.  Cappelletti M, Taddeo A, Colombo E, Brambilla L, Bellinvia M, Pregliasco F, Villa ML, Della Bella S. Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi's Sarcoma. J Invest Dermatol. 2012 Oct; 132(10):2414-21.

39.  Carrillo-Santisteve P, Lopalco PL. Measles still spreads in Europe: who is responsible for the failure to vaccinate? Clin Microbiol Infect. 2012 Oct;18 Suppl 5:50-6.

40.  Chan Soeung S, Grundy J, Duncan R, Thor R, Bilous JB. From reaching every district to reaching every community: analysis and response to the challenge of equity in immunization in Cambodia. Health Policy Plan. 2012 Oct 9. [Epub ahead of print].

41.  Chan TC, Hung IF, Luk JK, Shea YF, Chan FH, Woo PC, Chu LW. Prevention of Mortality and Pneumonia Among Nursing Home Older Adults by Dual Pneumococcal and  Seasonal Influenza Vaccination During a Pandemic Caused by Novel Pandemic Influenza A (H1N1). J Am Med Dir Assoc. 2012 Oct; 13(8):698-703.

42.  Chen JY, Chang CY, Lin YS, Hu ML. Nutritional Factors in Herpes Zoster, Postherpetic Neuralgia, and Zoster Vaccination. Popul Health Manag. 2012 Oct 22.  [Epub ahead of print].

43.  Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H. Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study. Clin Vaccine Immunol. 2012 Oct; 19(10):1597-602.

44.  Cho BH, Asay GR, Lorick SA, Tipton ML, Dube NL, Messonnier ML. Costs of School-Located Influenza Vaccination Clinics in Maine During the 2009-2010 H1N1 Pandemic. J Sch Nurs. 2012 Oct; 28(5):336-43.

45.  Choe YJ, Bae GR, Lee DH. No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: An ecological study. Vaccine. 2012 Oct 23. [Epub ahead of print].

46.  Christensen JJ, Humiston SG, Long CE, Kennedy AM, Dimattia K, Kolasa MS. Assessing the acceptability and feasibility of a school-located influenza vaccination program with third-party billing in elementary schools. J Sch Nurs. 2012 Oct; 28(5):344-51.

47.  Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of  the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr. 2012 Oct; 19(10):1132-9.

48.  Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012 Oct 4. [Epub ahead of print].

49.  Costa JT, Silva R, Tavares M, Nienhaus A. High effectiveness of pandemic influenza A (H1N1) vaccination in healthcare workers from a Portuguese hospital.  Int Arch Occup Environ Health. 2012 Oct; 85(7):747-52.

50.  Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis. 2012 Oct; 25(5):507-17.

51.  d'Onofrio A, Manfredi P, Poletti P. The interplay of public intervention and  private choices in determining the outcome of vaccination programmes. PLoS One. 2012;7(10):e45653.

52.  Darsley MJ, Chakraborty S, Denearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD. ACE527 Oral, Live Attenuated ETEC Vaccine Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease. Clin Vaccine Immunol. 2012 Oct 3. [Epub ahead of print].

53.  Dayan GH, Bevilacqua J, Coleman D, Buldo A, Risi G. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥50 years of age. Vaccine. 2012 Oct 19;30(47):6656-64.

54.  De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine. 2012 Oct 5; 30(45):6416-20.

55.  Deogaonkar R, Hutubessy R, Putten I, Evers S, Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health. 2012 Oct 16; 12(1):878. [Epub ahead of print].

56.  Desai SP, Lu B, Szent-Gyorgyi LE, Bogdanova AA, Turchin A, Weinblatt M, Coblyn J, Greenberg JO, Kachalia A, Solomon DH. Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial. Arthritis Rheum. 2012 Oct 8. [Epub ahead of print].

57.  Dey A, Wang H, Menzies R, Macartney K. Changes in hospitalisations for acute  gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust. 2012 Oct 15; 197(8):453-7.

58.  Diallo O, Schlumberger M, Sanou C, Dicko H, Aplogan A, Drabo F. [Use of SMS to ask mothers to come to vaccination sessions in Bobo-Dioulasso]. Bull Soc Pathol Exot. 2012 Oct;105(4):291-5.

59.  Domingues CM, Teixeira AM, Carvalho SM. National immunization program: vaccination, compliance and pharmacovigilance. Rev Inst Med Trop Sao Paulo. 2012  Oct;54 Suppl 18:22-7.

60.  Donadiki EM, Jiménez-García R, Hernandez-Barrera V, Carrasco-Garrido P, López de Andrés A, Jimenez-Trujillo I, Velonakis EG. Knowledge of the HPV vaccine and its association with vaccine uptake among female higher-education students in Greece. Hum Vaccin Immunother. 2012 Oct 30;9(2). [Epub ahead of print].

61.  Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL. First French Experience of ADR Reporting by Patients After a Mass Immunization Campaign with Influenza A (H1N1) Pandemic Vaccines: A Comparison of Reports Submitted by Patients and Healthcare Professionals. Drug Saf. 2012 Oct 1; 35(10):845-54.

62.  Edwards KM, Pung MA, Tomfohr LM, Ziegler MG, Campbell JP, Drayson MT, Mills PJ. Acute exercise enhancement of pneumococcal vaccination response: A randomized controlled trial of weaker and stronger immune response. Vaccine. 2012 Oct 5; 30(45):6389-95.

63.  Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE.  Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination. J Clin  Immunol. 2012 Oct 14. [Epub ahead of print].

64.  Elemraid MA, Rushton SP, Shirley MD, Thomas MF, Spencer DA, Eastham KM, Hampton F, Gorton R, Pollard K, Gennery AR, Clark JE. Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia. Epidemiol Infect. 2012 Oct 19:1-8. [Epub ahead of print].

65.  Ellis RD, Wu Y, Martin LB, Shaffer D, Miura K, Aebig J, Orcutt A, Rausch K, Zhu D, Mogensen A, Fay MP, Narum DL, Long C, Miller L, Durbin AP. Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria. PLoS One. 2012; 7(10):e46094.

66.  Englund H, Campe H, Hautmann W. Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season. Epidemiol Infect. 2012 Oct 26:1-9. [Epub ahead of print].

67.  Esen M, Mordmüller B, de Salazar PM, Adegnika AA, Agnandji ST, Schaumburg F,  Hounkpatin AB, Brückner S, Theisen M, Bélard S, Ngoa UA, Issifou S, Yazdanbakhsh  M, Kremsner PG. Reduced antibody responses against Plasmodium falciparum vaccine  candidate antigens in the presence of Trichuris trichiura. Vaccine. 2012 Oct 17.  [Epub ahead of print].

68.  Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, Amendola A, Fabiano V, Pivetti V, Zanetti A, Zuccotti GV. Vaccine. 2012 Oct 8. 10.1016/j.vaccine.2012.09.069. [Epub ahead of print].

69.  Esposito S, Bosis S, Morlacchi L, Baggi E, Sabatini C, Principi N. Can infants be protected by means of maternal vaccination? Clin Microbiol Infect. 2012 Oct; 18 Suppl 5:85-92.

70.  Etter DJ, Zimet GD, Rickert VI. Human papillomavirus vaccine in adolescent women: a 2012 update. Curr Opin Obstet Gynecol. 2012 Oct;24(5):305-10.

71.  Feavers I, Griffiths E, Baca-Estrada M, Knezevic I, Zhou T. WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3-4 October 2011. Biologicals. 2012 Oct 15. [Epub ahead of print].

72.  Fisman DN, Chan CH, Lowcock E, Naus M, Lee V. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: A model-based evaluation. Vaccine. 2012 Oct 26. [Epub ahead of print].

73.  Flegel K. Health care workers must protect patients from influenza by taking  the annual vaccine. CMAJ. 2012 Oct 29. [Epub ahead of print].

74.  Fukushima W, Ohfuji S, Deguchi M, Kawabata K, Hatayama H, Yoshida H, Maeda A, Hirota Y. Effectiveness of an influenza A (H1N1) 2009 monovalent vaccine among Japanese pregnant women: A prospective observational study assessing antibody efficacy. Vaccine. 2012 Oct 18. [Epub ahead of print].

75.  Gerberding J, Yawn BP. Discussing the Zoster Vaccine: An Interview with Julie Gerberding, President of Merck Vaccines. Popul Health Manag. 2012 Oct 22. [Epub ahead of print].

76.  Gerend MA, Shepherd JE. Predicting human papillomavirus vaccine uptake in young adult women: comparing the health belief model and theory of planned behavior. Ann Behav Med. 2012 Oct;44(2):171-80.

77.  Gessner BD. Ethnic disparities in influenza vaccination in Canada. CMAJ. 2012 Oct 16;184(15):1661-2.

78.  Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ, Fischer M, Staples JE. Detection of Anti-Yellow Fever Virus Immunoglobulin M Antibodies at 3-4 Years Following Yellow Fever Vaccination. Am J Trop Med Hyg. 2012 Oct 29. [Epub ahead of print]. 

79. Gilliland SM, Jenkins A, Parker L, Somdach N, Pattamadilok S, Incomserb P, Berry N, Schepelmann S, Minor P. Vaccine-related mumps infections in Thailand and the identification of a novel mutation in the mumps fusion protein. Biologicals.  2012 Oct 19. [Epub ahead of print].

80.  Goldman G, Miller N. Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010. Hum Exp Toxicol. 2012 Oct;31(10):1012-21.

81.  Gonzales JA, Levison AL, Stewart JM, Acharya NR, Margolis TP. Retinal necrosis following varicella-zoster vaccination. Arch Ophthalmol. 2012 Oct 1;130(10):1355-6.

82.  González-Vélez AE, Barrientos RR. [Considerations in the vaccination of adults with chronic kidney disease.]. Gac Sanit. 2012 Oct 16. [Epub ahead of print].

83.  Gowda C, Schaffer SE, Kopec K, Markel A, Dempsey AF. Does the relative importance of MMR vaccine concerns differ by degree of parental vaccine hesitancy?: An exploratory study. Hum Vaccin Immunother. 2012 Oct 2;8(12). [Epub  ahead of print].

84.  Grabenstein JD, Klugman KP. A century of pneumococcal vaccination research in humans. Clin Microbiol Infect. 2012 Oct; 18 Suppl 5:15-24.

85.  Greenwood B, Stuart JM. A vaccine to prevent epidemic meningitis in Africa.  Lancet Infect Dis. 2012 Oct; 12(10):738-9.

86.  Grimaldi-Bensouda L, Michel M, Aubrun E, Leighton P, Viallard JF, Adoue D, Magy-Bertrand N, Tisserand G, Khellaf M, Durand JM, Quittet P, Fain O, Bonnotte B, Morin AS, Limal N, Costedoat-Chalumeau N, Morel N, Pan-Petesch B, Decaux O, Mahevas M, Ruel M, Sacre K, Lefrere F, Abenhaim L, Godeau B. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood. 2012 Oct 24. [Epub ahead of print].

87.  Grzesiowski P, Aguiar-Ibáñez R, Kobryñ A, Durand L, Puig PE. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland. Hum Vaccin Immunother. 2012 Oct 1;8(10). [Epub ahead of print].

88.  Hariri S, Markowitz L. Monitoring HPV Vaccine Impact: Early Results and Ongoing Challenges. J Infect Dis. 2012 Oct 19. [Epub ahead of print].

89.  Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: A systematic review. Vaccine. 2012 Oct 3. [Epub ahead of print].

90.  He XS, Sasaki S, Baer J, Khurana S, Golding H, Treanor JJ, Topham DJ, Sangster MY, Jin H, Dekker CL, Subbarao K, Greenberg HB. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza A/H1N1 vaccine. J Infect Dis. 2012 Oct 29. [Epub ahead of print].

91.  Healy CM, Rench MA, Baker CJ. Importance of Timing of Maternal Tdap Immunization and Protection of Young Infants. Clin Infect Dis. 2012 Oct 26. [Epub ahead of print].

92.  Hedden EM, Jessop AB, Field RI. Childhood immunization reporting laws in the United States: Current status. Vaccine. 2012 Oct 3. [Epub ahead of print].

93.  Hellenbrand W, Elias J, Wichmann O, Dehnert M, Frosch M, Vogel U. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact  of vaccination with meningococcal C conjugate vaccine. J Infect. 2012 Oct 5. [Epub ahead of print].

94.  Hinson-Enslin A, Cardarelli R, Cardarelli KM. Clinical service characteristics and initiation of the human papillomavirus vaccination series in  an academic clinic setting. Tex Med. 2012 Oct 1; 108(10):e1.

95.  Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi MP, Tang Y, Marchetti E, Martellet L, Findlow H, Elie C, Parulekar V, Plikaytis B, Borrow R,  Carlone G, Kulkarni PS, Goel A, Suresh K, Beri S, Kapre S, Jadhav S, Preaud JM, Viviani S, Laforce FM. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: A Phase II/III double-blind randomized controlled trial. Vaccine. 2012 Oct 5; 30(45):6456-60.

96.  Holton A, Weberling B, Clarke CE, Smith MJ. The blame frame: media attribution of culpability about the MMR-autism vaccination scare. Health Commun. 2012 Oct; 27(7):690-701.

97.  Honarvar B, Odoomi N, Mahmoodi M, Kashkoli G, Khavandegaran F, Bagheri Lankarani K, Moghadami M. Acceptance and rejection of influenza vaccination by pregnant women in southern Iran: Physicians' role and barriers. Hum Vaccin Immunother. 2012 Oct 2; 8(12). [Epub ahead of print].

98.  Hughes B, Hayden F, Perikov Y, Hombach J, Tam JS. Report of the 5th meeting  on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011. Vaccine. 2012 Oct 19; 30(47):6612-22.

99. Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen  KY. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012 Oct 5; 30(45):6427-35.

100. Huynh S, Poduska P, Mallozzi T, Culler F. Mandatory influenza vaccination of health care workers: A first-year success implementation by a community health care system. Am J Infect Control. 2012 Oct; 40(8):771-3.

101. Igari H, Watanabe A, Segawa S, Suzuki A, Watanabe M, Sakurai T, Watanabe M,  Tatsumi K, Nakayama M, Suzuki K, Sato T. Immunogenicity of a Monovalent Pandemic  Influenza A H1N1 Virus Vaccine with or without Prior Seasonal Influenza Vaccine Administration. Clin Vaccine Immunol. 2012 Oct;19(10):1690-2.

102. Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev Pharmacoecon Outcomes Res.  2012 Oct 1. [Epub ahead of print].

103. Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X. A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany. Expert Rev Pharmacoecon Outcomes Res. 2012 Oct 1. [Epub ahead of print].

104. Johri M, Sharma JK, Jit M, Verguet S. Use of measles supplemental immunization activities (SIAs) as a delivery platform for other maternal and child health interventions: Opportunities and challenges. Vaccine. 2012 Oct 4. [Epub ahead of print].

105. Jokinen J, Palmu AA, Kilpi T. Acute Otitis Media Replacement and Recurrence  in the Finnish Otitis Media Vaccine Trial. Clin Infect Dis. 2012 Oct 16. [Epub ahead of print].

106. Jones AM, Omer SB, Bednarczyk RA, Halsey NA, Moulton LH, Salmon DA. Parents' source of vaccine information and impact on vaccine attitudes, beliefs, and nonmedical exemptions. Adv Prev Med. 2012; 2012:932741.

107. Kawakatsu Y, Honda S. Individual-, family- and community-level determinants  of full vaccination coverage among children aged 12-23 months in western Kenya. Vaccine. 2012 Oct 23. [Epub ahead of print].

108. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respi Viruses. 2012 Oct 19. [Epub ahead of print].

109. Khalil M, Al-Mazrou Y, Findlow H, Chadha H, Bosch Castells V, Johnson DR, Borrow R. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old saudi arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine. Clin Vaccine Immunol. 2012 Oct; 19(10):1561-6.

110. Kharbanda EO, Parker ED, Nordin JD, Hedblom BD, Rolnick SJ. Influenza and Pertussis Vaccination Coverage Among Privately Insured Women of Reproductive Age. Matern Child Health J. 2012 Oct 30. [Epub ahead of print].

111. Khatami A, Snape MD, Wysocki J, John TM, Westcar S, Mesaros N, Peddiraju K,  Boutriau D, Yu LM, Pollard AJ. Persistence of Antibody Response Following a Booster Dose of Hib-MenC-TT Glycoconjugate Vaccine to Five Years: A Follow-up Study. Pediatr Infect Dis J. 2012 Oct; 31(10):1069-73.

112. Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, Cheetham TC, Liaw KL, Takhar H, Jacobsen SJ. Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females. Arch Pediatr Adolesc Med. 2012 Oct 1:1-9. [Epub ahead of print].

113. Klimov AI, Garten R, Russell C, Barr IG, Besselaar TG, Daniels R, Engelhardt OG, Grohmann G, Itamura S, Kelso A, McCauley J, Odagiri T, Smith D, Tashiro M, Xu X, Webby R, Wang D, Ye Z, Yuelong S, Zhang W, Cox N; Writing Committee of the World Health Organization Consultation on Southern Hemisphere Influenza Vaccine Composition for 2012. WHO recommendations for the viruses to be used in the 2012  Southern Hemisphere Influenza Vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine. 2012 Oct 5; 30(45):6461-71.

114. Kositanont U, Assantachai P, Wasi C, Puthavathana P, Praditsuwan R. Kinetics of the Antibody Response to Seasonal Influenza Vaccination Among the Elderly. Viral Immunol. 2012 Oct 12. [Epub ahead of print].

115. Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA. Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity. Clin Infect Dis. 2012 Oct 19. [Epub ahead of print].

116. Kuo AM, Brown JN, Clinard V. Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy. J Clin Pharm Ther. 2012 Oct; 37(5):505-9.

117. Lachiany M, Stone L. A vaccination model for a multi-city system. Bull Math  Biol. 2012 Oct;74(10):2474-87.

118. Lambert SB. Postherpetic neuralgia after herpes zoster vaccination. JAMA. 2012 Oct 10; 308(14):1427; author reply 1427-8.

119. Lambert SB, Sheridan SL, Grimwood K. Canadian rotavirus vaccine effectiveness data. Can Fam Physician. 2012 Oct; 58(10):1081.

120. Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Rev Inst Med Trop Sao Paulo. 2012 Oct; 54 Suppl 18:15-7.

121. Langley JM, Frenette L, Chu L, McNeil S, Halperin S, Li P, Vaughn D. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infect Dis. 2012 Oct 30; 12(1):279. [Epub ahead of print].

122. Laurichesse H, Zimmermann U, Galtier F, Launay O, Duval X, Richard P, Sadorge C, Soubeyrand B. Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX (®) ) and a tetanus monovalent vaccine in healthy adults: New considerations for the management of patients with tetanus-prone injuries. Hum Vaccin Immunother. 2012 Oct 2; 8(12). [Epub ahead of print].

123. Lavail KH, Kennedy AM. The Role of Attitudes About Vaccine Safety, Efficacy, and Value in Explaining Parents' Reported Vaccination Behavior. Health Educ Behav. 2012 Oct 25. [Epub ahead of print].

124. Le Corre N, Thibault F, Noble CP, Meiffrédy V, Daoud S, Cahen R, Charreau I, Bottigioli D, Dollinger C, Aboulker JP, Autran B, Morelon E, Barrou B. Effect of  two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Vaccine. 2012 Oct 25. [Epub ahead of print].

125. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012 Oct 18. [Epub ahead of print].

126. Lehtinen M. Cross-protection is crucial for prophylactic HPV vaccination. Lancet Infect Dis. 2012 Oct; 12(10):742-3.

127. Lemaître C, Ferroni A, Doit C, Vu-Thien H, Glorion C, Raymond J, Mary P, Wicart P, Bingen E, Ilharreborde B, Lorrot M. Pediatric osteoarticular infections caused by Streptococcus pneumoniae before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2012 Oct; 31(10):2773-81.

128. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in  young and older adults. J Infect Dis. 2012 Oct; 206(8):1280-90.

129. Levine H, Ankol OE, Rozhavski V, Davidovitch N, Aboudy Y, Zarka S, Balicer RD. Rubella seroprevalence in the first birth cohort reaching fertility age after 20 years of two dose universal vaccination policy in Israel. Vaccine. 2012 Oct 10. [Epub ahead of print].

130. Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during  the first year of life. Vaccine. 2012 Oct 18. [Epub ahead of print].

131. Lilja AE, Mason PW. The next generation recombinant human cytomegalovirus vaccine candidates-Beyond gB. Vaccine. 2012 Oct 3. [Epub ahead of print].

132. Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect. 2012 Oct; 18 Suppl 5:93-9.

133. Lopes CC, Berezin EN, Scheffer D, Huziwara R, Sliva MI, Brandão A, Guerra ML, Brandileone MC. Pneumococcal Nasopharyngeal Carriage in Infants of Mothers Immunized with 23V Non-conjugate Pneumococcal Polysaccharide Vaccine. J Trop Pediatr. 2012 Oct; 58(5):348-52. 

134. Lou Y, Qesmi R, Wang Q, Steben M, Wu J, Heffernan JM. Epidemiological impact of a genital herpes type 2 vaccine for young females. PLoS One. 2012; 7(10):e46027.

135. Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, Casey C, Dekker C, Edwards KM, Klein J, Klein NP, Larussa P, Sparks R, Jakob K. Causality assessment of advers events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012 Oct 9. [Epub ahead of print].

136. Lu DM. Recent development in aerosol devices for pulmonary vaccine delivery. Beijing Da Xue Xue Bao. 2012 Oct 18; 44(5):683-7.

137. Lund N, Andersen A, Monteiro I, Aaby P, Benn CS. No effect of oral polio vaccine administered at birth on mortality and immune response to BCG. A natural  experiment. Vaccine. 2012 Oct 19; 30(47):6694-9.

138. László B, Kónya J, Dandár E, Deák J, Farkas Á, Gray J, Grósz G, Iturriza-Gomara M, Jakab F, Juhász Á, Kisfali P, Kovács J, Lengyel G, Martella V, Melegh B, Mészáros J, Molnár P, Nyúl Z, Papp H, Pátri L, Puskás E, Sántha I, Schneider F, Szomor K, Tóth A, Tóth E, Szûcs G, Bányai K. Surveillance of human rotaviruses in 2007-2011, Hungary: exploring the genetic relatedness between vaccine and field strains. J Clin Virol. 2012 Oct; 55(2):140-6.

139. Macias VC, Cunha D. Psoriasis triggered by tetanus-diphtheria vaccination. Cutan Ocul Toxicol. 2012 Oct 10. [Epub ahead of print] PubMed PMID:

140. Mak DB, Carcione D, Joyce S, Tomlin S, Effler PV. Paediatric influenza vaccination program suspension: effect on childhood vaccine uptake. Aust N Z J Public Health. 2012 Oct; 36(5):494-5.

141. Marcos AC, Pelissoni FD, Cunegundes KS, Abramczyk ML, Bellei NC, Sanches NA, Moraes-Pinto MI. Pediatric hospital admissions from influenza A (H1N1) in Brazil: effects of the 2010 vaccination campaign. Clinics (Sao Paulo). 2012 Oct; 67(10):1215-8.

142. Martin LB. Vaccines for typhoid fever and other salmonelloses. Curr Opin Infect Dis. 2012 Oct; 25(5):489-99.

143. Martin S, Costa A, Perea W. Stockpiling oral cholera vaccine. Bull World Health Organ. 2012 Oct 1; 90(10):714.

144. Mazza D, Petrovic K, Chakraborty S. HPV vaccination of adult women: An audit of Australian general practitioners. Aust N Z J Obstet Gynaecol. 2012 Oct 10. [Epub ahead of print].

145. McCormick EV, Durfee J, Vogt TM, Daley MF, Hambidge SJ, Shlay J. Physician Attitudes Regarding School-Located Vaccinations. Pediatrics. 2012 Oct 1. [Epub ahead of print].

146. Menni F, Chiarelli G, Sabatini C, Principi N, Esposito S. Vaccination in children with inborn errors of metabolism. Vaccine. 2012 Oct 18. [Epub ahead of print].

147. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P. 1976  and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies  in Humans. J Infect Dis. 2012 Oct 18. [Epub ahead of print].

148. Minetti A, Riera-Montes M, Nackers F, Roederer T, Koudika MH, Sekkenes J, Taconet A, Fermon F, Touré A, Grais RF, Checchi F. Performance of small cluster surveys and the clustered LQAS design to estimate local-level vaccination coverage in Mali. Emerg Themes Epidemiol. 2012 Oct 12; 9(1):6. [Epub ahead of print].

149. Mishra RP, Oviedo-Orta E, Prachi P, Rappuoli R, Bagnoli F. Vaccines and antibiotic resistance. Curr Opin Microbiol. 2012 Oct; 15(5):596-602.

150. Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, Descamps D, Schuind A. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously  vaccinated adult women. Vaccine. 2012 Oct 11. [Epub ahead of print].

151. Müller-Ladner C, Müller-Ladner U. [Vaccinations in patients with autoimmune  inflammatory rheumatic diseases--EULAR recommendations for pediatric and adult patients]. Med Monatsschr Pharm. 2012 Oct; 35(10):353-64; quiz 365-6.

152. Nagaoka K, Fujiwara T, Ito J. Do income inequality and social capital associate with measles-containing vaccine coverage rate? Vaccine. 2012 Oct 26. [Epub ahead of print].

153. Nakayama T, Kumagai T, Ishii KJ, Ihara T. Alum-adjuvanted H5N1 whole virion  inactivated vaccine (WIV) induced IgG1 and IgG4 antibody responses in young children. Vaccine. 2012 Oct 23. [Epub ahead of print].

154. Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, Lizama A, Diras D, Mathew A, Camacho EJ, Monforte MN, Chen TH, Mahamud A, Kutty PK, Hickman C, Bellini WJ, Seward JF, Gallagher K, Fiebelkorn AP. Epidemiology of a Mumps Outbreak in a Highly Vaccinated Island Population and Use of a Third Dose of Measles-Mumps-Rubella Vaccine for Outbreak Control- Guam 2009-2010. Pediatr Infect Dis J. 2012 Oct 24. [Epub ahead of print].

155. Nguyen S, Huleux T, Choisy P, Senneville E, Ajana F. Vaccinal issues between Belgian and French travelers. Med Mal Infect. 2012 Oct 15. [Epub ahead of print].

156. Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré  L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012 Oct;12(10):757-64.

157. Ofstead CL, Sherman BW, Wetzler HP, Dirlam Langlay AM, Mueller NJ, Ward JM,  Ritter DR, Poland GA. Effectiveness of Worksite Interventions to Increase Influenza Vaccination Rates Among Employees and Families. J Occup Environ Med. 2012 Oct 8. [Epub ahead of print].

158. Olyarchuk LD, Willoughby D, Davis SC, Newsom SA. Examining the benefit of vaccinating adults against pertussis. J Am Acad Nurse Pract. 2012 Oct; 24(10):587-94.

159. Orenstein LA, Orenstein EW, Teguete I, Kodio M, Tapia M, Sow SO, Levine MM.  Background rates of adverse pregnancy outcomes for assessing the safety of maternal vaccine trials in sub-saharan Africa. PLoS One. 2012;7(10):e46638.

160. Pappas-Rogich M. Faith community nurses: protecting our elders through immunizations. J Christ Nurs. 2012 Oct-Dec; 29(4):232-7.

161. Patel MM, Clark AD, Sanderson CF, Tate J, Parashar UD. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med. 2012 Oct; 9(10):e1001330.

162. Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA. Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes. J Infect Dis. 2012 Oct;206(7):1069-77.

163. Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJ. A(H1N1)pdm09 Vaccination of Health Care Workers: Improved Immune Responses in Low Responders Following Revaccination. J Infect Dis. 2012 Oct 12. [Epub ahead of print].

164. Peeters M, Regner S, Vaman T, Devaster JM, Rombo L. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials. Vaccine. 2012 Oct 5; 30(45):6483-91.

165. Peterson RM, Cook C, Yerxa ME, Marshall JH, Pulos E, Rollosson MP. Improving immunization coverage in a rural school district in pierce county, washington. J  Sch Nurs. 2012 Oct; 28(5):352-7.

166. Pittet LF, Posfay-Barbe KM. Pneumococcal vaccines for children: a global public health priority. Clin Microbiol Infect. 2012 Oct; 18 Suppl 5:25-36.

167. Pronker ES, Claassen E, Osterhaus AD. Development of new generation influenza vaccines: Recipes for success? Vaccine. 2012 Oct 5. [Epub ahead of print].

168. Quach S, Hamid JS, Pereira JA, Heidebrecht CL, Deeks SL, Crowcroft NS, Quan  SD, Brien S, Kwong JC; for the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Vaccine Coverage Theme Group. Influenza vaccination coverage across ethnic groups in Canada. CMAJ. 2012 Oct 16; 184(15):1673-1681.

169. Quintana LF, Serra N, De Molina-Llauradó P, Blasco M, Martinez M, Campos B,  Bayas JM, Pumarola T, Campistol JM. Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine. Influenza Other Respi Viruses. 2012 Oct 19. [Epub ahead of print].

170. Reilly BK, Reddy SK, Verghese ST. Acute epiglottitis in the era of post-Haemophilus influenzae type B (HIB) vaccine. J Anesth. 2012 Oct 18. [Epub ahead of print].

171. Reimer RA, Houlihan AE, Gerrard M, Deer MM, Lund AJ. Ethnic Differences in Predictors of HPV Vaccination: Comparisons of Predictors for Latina and Non-Latina White Women. J Sex Res. 2012 Oct 2. [Epub ahead of print].

172. Renner B, Reuter T. Predicting vaccination using numerical and affective risk perceptions: The case of A/H1N1 influenza. Vaccine. 2012 Oct 6. [Epub ahead of print].

173. Ressel G. ACIP Updates Guideline on Influenza Vaccination for 2012-2013 Season. Am Fam Physician. 2012 Oct 1; 86(7):686-90.

174. Reynales H, Astudillo P, de Vallière S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Fariña A, Sales-Carmona V, Groth N. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5; 30(45):6436-43. 

175. Riley LE, Beigi RH. Maternal Pertussis vaccination: protecting neonates from infection. Clin Infect Dis. 2012 Oct 24. [Epub ahead of print].

176. Rodenburg GD, Sanders EA, van Gils EJ, Veenhoven RH, Zborowski T, van den Dobbelsteen GP, Bloem AC, Berbers GA, Bogaert D. Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life. PLoS One. 2012; 7(10):e46916.

177. Ruiz-Palacios GM, Huang LM, Lin TY, Hernandez L, Guerrero ML, Villalobos AL, Van der Wielen M, Moreira M, Fissette L, Borys D, Miller JM. Immunogenicity and Safety of a Booster Dose of the 10-Valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Co-Administered with the Tetravalent Meningococcal Serogroups A, C, W-135, and Y Tetanus Toxoid Conjugate Vaccine in Toddlers: A Randomized Trial. Pediatr Infect Dis J. 2012 Oct 16. [Epub ahead of print].

178. Sato H, Sakurai Y. The contribution of residents who cooperate with ring-vaccination measures against smallpox epidemic. Disaster Med Public Health Prep. 2012 Oct; 6(3):270-6.

179. Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in zanzibar.  PLoS Negl Trop Dis. 2012 Oct;6(10):e1844.

180. Schlaudecker EP, McNeal MM, Dodd CN, Ranz JB, Steinhoff MC. Pregnancy Modifies the Antibody Response to Trivalent Influenza Immunization. J Infect Dis. 2012 Oct 12. [Epub ahead of print]

181. Scott LJ, Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) : a guide to its use in older adults. Drugs Aging. 2012 Oct; 29(10):847-55.

182. Seale H, Trung L, Mackie FE, Kennedy SE, Boros C, Marshall H, Tidswell J, Shaw PJ, Montgomery K, Macintyre CR. A qualitative study investigating knowledge  and attitudes regarding human papillomavirus (HPV) and the HPV vaccine among parents of immunosuppressed children. Vaccine. 2012 Oct 8. [Epub ahead of print].

183. Seo YB, Hong KW, Kim IS, Choi WS, Baek JH, Lee J, Song JY, Lee JS, Cheong HJ, Kim WJ. Effectiveness of the influenza vaccine at preventing hospitalization  due to acute lower respiratory infection and exacerbation of chronic cardiopulmonary disease in Korea during 2010-2011. Vaccine. 2012 Oct 18. [Epub ahead of print].

184. Shahrabani S, Benzion U. How experience shapes health beliefs: the case of influenza vaccination. Health Educ Behav. 2012 Oct; 39(5):612-9.

185. Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, Beall B, Satola S, Jerris R, Jain S, Farley MM, Nuorti JP. Pneumococcal Carriage  and Invasive Disease in Children before Introduction of the 13-valent Conjugate Vaccine: Comparison with the Pre-7-valent Conjugate Vaccine Era. Pediatr Infect Dis J. 2012 Oct 17. [Epub ahead of print].

186. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins  KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss  CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ. ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Mol Ther. 2012 Oct 23. [Epub ahead of print].

187. Sheldon EA, Jeanfreau R, Sliman JA, Charenkavanich S, Rousculp MD, Dubovsky  F, Mallory RM. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated  influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*. Influenza Other Respi Viruses. 2012 Oct 14. doi: 10.1111/irv.12027. [Epub ahead of print].

188. Shen Z, Lei H. Expression of hBD-2 induced by 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b vaccine and split influenza virus vaccine. Mol Med Report. 2012 Oct; 6(4):733-8.

189. Shim E, Galvani AP. Distinguishing vaccine efficacy and effectiveness. Vaccine. 2012 Oct 19; 30(47):6700-5.

190. Shimazawa R, Ikeda M. The vaccine gap between Japan and the UK. Health Policy. 2012 Oct; 107(2-3):312-7.

191. Shimizu M, Ueno K, Yachie A. Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab. Clin Vaccine Immunol. 2012 Oct; 19(10):1700-2.

192. Simell B, Nurkka A, Ekström N, Givon-Lavi N, Käyhty H, Dagan R. Serum IgM Antibodies Contribute to High Levels of Opsonophagocytic Activities in Toddlers Immunized with a Single Dose of the 9-Valent Pneumococcal Conjugate Vaccine. Clin Vaccine Immunol. 2012 Oct; 19(10):1618-23.

193. Smith-Norowitz TA, Kusonruksa M, Wong D, Norowitz MM, Joks R, Durkin HG, Bluth MH. Long-term persistence of IgE anti-influenza A HIN1 virus antibodies in  serum of children and adults following influenza A vaccination with subsequent H1N1 infection: a case study. J Inflamm Res. 2012; 5:111-6.

194. Soriano A, Manna R. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: Comparing different experiences. J Dermatol. 2012 Oct; 39(10):888-9.

195. Stadlin S, Bednarczyk RA, Omer SB. Medical exemptions to school immunization requirements in the United States--association of state policies with medical exemption rates (2004-2011). J Infect Dis. 2012 Oct; 206(7):989-92.

196. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson  D, McNamee K, Garefalakis M, Garland SM. Fall in Human Papillomavirus Prevalence  Following a National Vaccination Program. J Infect Dis. 2012 Oct 24. [Epub ahead of print].

197. Tafuri S, Martinelli D, Prato R, Germinario C. Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in a region which adopted UMV. Hum Vaccin Immunother. 2012 Oct 29; 9(1). [Epub ahead of print].

198. Talbot TR, Babcock H, Cotton D, Maragakis LL, Poland GA, Septimus EJ, Tapper ML, Weber DJ. The Use of Live Attenuated Influenza Vaccine (LAIV) in Healthcare Personnel (HCP): Guidance from the Society for Healthcare Epidemiology of America (SHEA). Infect Control Hosp Epidemiol. 2012 Oct; 33(10):981-3.

199. Tanne JH. Girls do not see HPV vaccine as green light for sex, study says. BMJ. 2012 Oct 23; 345:e7159.

200. Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clinicoecon Outcomes Res. 2012; 4:287-98.

201. Tejedor JC, Merino JM, Moro M, Navarro ML, Espín J, Omeñaca F, García-Sicilia J, Moreno-Pérez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM,  Mesaros N. Five-year Antibody Persistence and Safety Following a Booster Dose of  Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine. Pediatr Infect Dis J. 2012 Oct; 31(10):1074-1077.

202. Tetsutani K, Ishii KJ. Adjuvants in influenza vaccines. Vaccine. 2012 Oct 18. [Epub ahead of print].

203. Theidel U, Braem A, Rückinger S. [Determination of Vaccination Quotas for Pneumococcal Conjugate Vaccine in Children on the Basis of Routine Data of the Statutory Health Insurance.]. Gesundheitswesen. 2012 Oct 16. [Epub ahead of print].

204. Tonnis WF, Kersten GF, Frijlink HW, Hinrichs WL, de Boer AH, Amorij JP. Pulmonary vaccine delivery: a realistic approach? J Aerosol Med Pulm Drug Deliv.  2012 Oct; 25(5):249-60.

205. Toptygina A, Semikina E, Alioshkin V. Influence of an immunopotentiator Polyoxidonium on cytokine profile and antibody production in children vaccinated  with Priorix. Arch Physiol Biochem. 2012 Oct; 118(4):197-203.

206. Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breese Hall C, Monto AS, Griffin  MR, Belongia E, Shay DK; for the US Flu-VE Network. Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains. Clin Infect Dis. 2012 Oct; 55(7):951-959.

207. Tsui J, Gee GC, Rodriguez HP, Kominski GF, Glenn BA, Singhal R, Bastani R. Exploring the Role of Neighborhood Socio-Demographic Factors on HPV Vaccine Initiation Among Low-Income, Ethnic Minority Girls. J Immigr Minor Health. 2012 Oct 19. [Epub ahead of print].

208. Uzicanin A, Thompson M, Smith P, Chaves SS, Foster L, Dube N, Graitcer S, Jackson R, Ferdinands J, Gargiullo P, Mills D, Monto AS, Shay DK; on behalf of the Maine 2009 Influenza A (H1N1) Vaccine Effectiveness Evaluation Group. Effectiveness of 1 Dose of Influenza A (H1N1) 2009 Monovalent Vaccines in Preventing Reverse-Transcription Polymerase Chain Reaction-Confirmed H1N1 Infection Among School-Aged Children in Maine. J Infect Dis. 2012 Oct; 206(7):1059-1068.

209. Verma R, Khanna P. Tetanus toxoid vaccine: Elimination of neonatal tetanus in selected states of India. Hum Vaccin Immunother. 2012 Oct 1; 8(10). [Epub ahead of print].

210. Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. A  randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 y. Hum Vaccin Immunother. 2012 Oct 2; 8(12). [Epub ahead of print].

211. Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012 Oct 2; 8(12). [Epub ahead of print].

212. Vesikari T. Rotavirus vaccination: a concise review. Clin Microbiol Infect.  2012 Oct; 18 Suppl 5:57-63.

213. Vrethem M, Malmgren K, Lindh J. A patient with both narcolepsy and multiple  sclerosis in association with Pandemrix vaccination. J Neurol Sci. 2012 Oct 15; 321(1-2):89-91.

214. Wang L, Lei D, Zhang S. Acellular pertussis vaccines in China. Vaccine. 2012 Oct 18. [Epub ahead of print].

215. Watts G. Tuberculosis experts pin hopes of controlling disease on 12 vaccines in development. BMJ. 2012 Oct 16; 345:e6981.

216. Weckx LY, Thompson A, Berezin EN, Faria SM, Cunha CA, Pride M, Patterson S,  Gruber WC, Emini EA, Scott DA; On behalf of the 012 Study Group. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012 Oct 22. [Epub ahead of print].

217. Weinberger B, Grubeck-Loebenstein B. Vaccines for the elderly. Clin Microbiol Infect. 2012 Oct;18 Suppl 5:100-8.

218. Wieten RW, Leenstra T, van Thiel PP, van Vugt M, Stijnis C, Goorhuis A, Grobusch MP. Rabies vaccinations: are abbreviated intradermal schedules the future? Clin Infect Dis. 2012 Oct 26. [Epub ahead of print].

219. Wilby KJ, Werry D. A review of the effect of immunization programs on antimicrobial utilization. Vaccine. 2012 Oct 12; 30(46):6509-14.

220. Williams DJ, Edwards KM, Payne DC, Manning J, Parashar UD, Lopman BA. Decline in gastroenteritis-related triage calls after rotavirus vaccine licensure. Pediatrics. 2012 Oct; 130(4):e872-8.

221. Williams NJ, Ghosh TS, Vogt RL. Needlestick injury surveillance during mass  vaccination clinics: Lessons learned and why more is needed-Tri-County (Denver Metropolitan) region, Colorado, 2009. Am J Infect Control. 2012 Oct; 40(8):768-70.

222. Wiwanitkit V. Missed appointment in rabies vaccination schedule. Arq Neuropsiquiatr. 2012 Oct; 70(10):834.

223. Wong KY, Do YK. Are there socioeconomic disparities in women having discussions on human papillomavirus vaccine with health care providers? BMC Womens Health. 2012 Oct 4; 12(1):33. [Epub ahead of print].

224. Yang ZJ. Too Scared or Too Capable? Why Do College Students Stay Away from the H1N1 Vaccine? Risk Anal. 2012 Oct; 32(10):1703-16.

[Top]